Literature DB >> 29430582

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Bart A W Jacobs1,2, Nikol Snoeren3, Morsal Samim3, Hilde Rosing2, Niels de Vries2, Maarten J Deenen1, Jos H Beijnen2,4, Jan H M Schellens1,4, Miriam Koopman5, Richard van Hillegersberg6.   

Abstract

PURPOSE: The dihydrouracil (DHU):uracil (U) plasma ratio is a promising marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient patients. The objective of this study was to determine the effect of liver resection on the DHU:U plasma ratio in patients with colorectal liver metastases (CRLM).
METHODS: An observational study was performed in which DHU:U plasma ratios in patients with CRLM were analyzed prior to and 1 day after liver resection. In addition, the DHU:U plasma ratio was quantified in six additional patients 4-8 weeks after liver resection to explore long-term effects on the DHU:U plasma ratio. Quantification of U and DHU plasma levels was performed using a validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay.
RESULTS: The median (range) DHU:U plasma ratio in 15 patients prior to liver resection was 10.7 (2.6-14.4) and was significantly reduced to 5.5 (< quantification limit (LLOQ-10.5) 1 day after resection (p = 0.0026). This reduction was caused by a decrease in DHU plasma levels from 112.0 (79.8-153) ng/mL to 41.2 (< LLOQ-160) ng/mL 1 day after resection (p = 0.0004). Recovery of the DHU:U plasma ratio occurred 4-8 weeks after liver resection, which was shown by a median (range) DHU:U plasma ratio in six patients of 9.1 (6.9-14.5).
CONCLUSION: Liver resection leads to very low DHU:U plasma ratios 1 day after liver resection, which is possibly caused by a reduction in DPD activity. Quantification of the DHU:U plasma ratios directly after liver resection could lead to false-positive identification of DPD deficiency and is therefore not advised.

Entities:  

Keywords:  5-Fluorouracil; Capecitabine; Dihydropyrimidine dehydrogenase; Dihydrouracil; Liver resection; Uracil

Mesh:

Substances:

Year:  2018        PMID: 29430582     DOI: 10.1007/s00228-018-2426-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true?

Authors:  M M Borner
Journal:  Ann Oncol       Date:  1999-06       Impact factor: 32.976

Review 2.  Safety of capecitabine: a review.

Authors:  Sameh E Mikhail; Jun F Sun; John L Marshall
Journal:  Expert Opin Drug Saf       Date:  2010-09       Impact factor: 4.250

3.  Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Authors:  Bart A W Jacobs; Maarten J Deenen; Dick Pluim; J G Coen van Hasselt; Martin D Krähenbühl; Robin M J M van Geel; Niels de Vries; Hilde Rosing; Didier Meulendijks; Artur M Burylo; Annemieke Cats; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

4.  Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.

Authors:  A B Van Kuilenburg; H Van Lenthe; A Tromp; P C Veltman; A H Van Gennip
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

5.  Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

Authors:  Dick Pluim; Bart A W Jacobs; Maarten J Deenen; Anneloes E M Ruijter; Robin M J M van Geel; Artur M Burylo; Didier Meulendijks; Jos H Beijnen; Jan H M Schellens
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

6.  The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.

Authors:  Zhi Wei Zhou; Guo Qiang Wang; De Sen Wan; Zhen Hai Lu; Ying Bo Chen; Su Li; Gong Chen; Zhi Zhong Pan
Journal:  Chemotherapy       Date:  2007-02-16       Impact factor: 2.544

7.  Assessment of hepatic functional regeneration after hepatectomy using (99m)Tc-GSA SPECT/CT fused imaging.

Authors:  Morikatsu Yoshida; Shinya Shiraishi; Fumi Sakamoto; Toru Beppu; Daisuke Utsunomiya; Hirohisa Okabe; Seiji Tomiguchi; Hideo Baba; Yasuyuki Yamashita
Journal:  Ann Nucl Med       Date:  2014-07-08       Impact factor: 2.668

8.  Colorectal liver metastases.

Authors:  Ashraf J Haddad; Murad Bani Hani; Timothy M Pawlik; Steven C Cunningham
Journal:  Int J Surg Oncol       Date:  2011-06-06

9.  Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.

Authors:  Nikol Snoeren; Richard van Hillegersberg; Sander B Schouten; Andre M Bergman; Erikv van Werkhoven; Otilia Dalesio; Rob A E M Tollenaar; Henk M Verheul; Joost van der Sijp; Inne H M Borel Rinkes; E E Voest
Journal:  Neoplasia       Date:  2017-01-12       Impact factor: 5.715

10.  Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.

Authors:  A Loganayagam; M Arenas Hernandez; A Corrigan; L Fairbanks; C M Lewis; P Harper; N Maisey; P Ross; J D Sanderson; A M Marinaki
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.